MX2013007336A - Compuestos de bi-heteroarilo como inhibidores de vps34. - Google Patents

Compuestos de bi-heteroarilo como inhibidores de vps34.

Info

Publication number
MX2013007336A
MX2013007336A MX2013007336A MX2013007336A MX2013007336A MX 2013007336 A MX2013007336 A MX 2013007336A MX 2013007336 A MX2013007336 A MX 2013007336A MX 2013007336 A MX2013007336 A MX 2013007336A MX 2013007336 A MX2013007336 A MX 2013007336A
Authority
MX
Mexico
Prior art keywords
vps34
heteroaryl compounds
inhibitors
disease
treating
Prior art date
Application number
MX2013007336A
Other languages
English (en)
Inventor
Ayako Honda
Ivan Cornella Taracido
Edmund Martin Harrington
Erin Keaney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013007336A publication Critical patent/MX2013007336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente invención incluye novedosos métodos para el tratamiento de una enfermedad o de un trastorno caracterizado por hiperactividad de Vps34, y compuestos como inhibidores de Vps34; en particular los compuestos de la fórmula I: (Ver Formula) o una sal farmacéuticamente aceptable de los mismos, así como los métodos para el tratamiento de una enfermedad, trastorno, o síndrome asociado con la inhibición de Vps34, en particular de las enfermedades hiperproliferativas. La presente invención también incluye composiciones farmacéuticas, incluyendo los compuestos de la fórmula 1 y las sales farmacéuticamente aceptables de los mismos.
MX2013007336A 2010-12-21 2011-12-19 Compuestos de bi-heteroarilo como inhibidores de vps34. MX2013007336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425416P 2010-12-21 2010-12-21
PCT/IB2011/055772 WO2012085815A1 (en) 2010-12-21 2011-12-19 Bi-heteroaryl compounds as vps34 inhibitors

Publications (1)

Publication Number Publication Date
MX2013007336A true MX2013007336A (es) 2013-08-01

Family

ID=45509576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007336A MX2013007336A (es) 2010-12-21 2011-12-19 Compuestos de bi-heteroarilo como inhibidores de vps34.

Country Status (11)

Country Link
US (2) US8685993B2 (es)
EP (1) EP2655340B1 (es)
JP (1) JP2014500308A (es)
KR (1) KR20130130030A (es)
CN (1) CN103270026A (es)
AU (1) AU2011346567A1 (es)
BR (1) BR112013015449A2 (es)
CA (1) CA2822565A1 (es)
EA (1) EA201390917A1 (es)
MX (1) MX2013007336A (es)
WO (1) WO2012085815A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095846B2 (en) * 2011-09-13 2015-08-04 Brookhaven Science Associates, Llc Bimetallic catalysts for CO2 hydrogenation and H2 generation from formic acid and/or salts thereof
US9315381B2 (en) * 2012-01-27 2016-04-19 National Institute Of Advanced Industrial Science And Technology Dehydrogenation catalyst for formic acid, method for producing hydrogen, and method for producing heavy-hydrogen gas or heavy-hydrogenated hydrogen
EP2910130B1 (en) * 2012-10-18 2018-08-15 Nissin Foods Holdings Co., Ltd. Salty taste-enhancing agent and manufacturing method therefor, and salty taste-enhancing method
KR20150142014A (ko) 2013-04-12 2015-12-21 바이엘 크롭사이언스 악티엔게젤샤프트 신규 트리아졸 유도체
JP2016522800A (ja) 2013-04-12 2016-08-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規トリアゾリンチオン誘導体
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MY182908A (en) * 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof
BR112017021109A2 (pt) 2015-04-02 2018-07-03 Bayer Cropscience Ag derivados de triazol como fungicidas
PE20180175A1 (es) 2015-04-02 2018-01-22 Bayer Cropscience Ag Nuevos derivados de imidazolilmetilo 5-sustituidos
CA3015005A1 (en) 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2017140841A1 (en) * 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
WO2018050456A1 (en) 2016-09-13 2018-03-22 Bayer Cropscience Aktiengesellschaft Active compound combinations comprising a 5-substituted imidazole derivative
WO2018060074A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
EP3519392A1 (en) 2016-09-29 2019-08-07 Bayer CropScience Aktiengesellschaft Novel 5-substituted imidazole derivatives
US20200045972A1 (en) 2016-09-29 2020-02-13 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
US11219618B2 (en) * 2017-08-23 2022-01-11 Sprint Bioscience Ab Pyridylpyridone compounds
HUE060805T2 (hu) * 2017-08-23 2023-04-28 Sprint Bioscience Ab Piridinamin-piridon és pirimidinamin-piridon vegyületek
EP3672962B1 (en) 2017-08-23 2022-01-26 Sprint Bioscience AB Morpholinylpyridone compounds
DK3672967T3 (da) 2017-08-23 2022-01-10 Sprint Bioscience Ab Azaindolylpyridon- og diazaindolylpyridonforbindelser
WO2019092086A1 (en) 2017-11-13 2019-05-16 Bayer Aktiengesellschaft Tetrazolylpropyl derivatives and their use as fungicides
TW202120495A (zh) * 2019-08-02 2021-06-01 美商愛彼特生物製藥股份有限公司 經取代環丙基—２，２＇—聯嘧啶基化合物、其類似物及其使用方法
IT202000001567A1 (it) * 2020-01-28 2021-07-28 Univ Degli Studi Padova Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi.
CN117083064A (zh) 2020-11-25 2023-11-17 德西费拉制药有限责任公司 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO1997033883A1 (en) 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
CA2422380C (en) 2000-09-15 2009-03-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
WO2005035507A2 (en) 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
BRPI0415678A (pt) 2003-10-23 2006-12-19 Pharmacia Corp compostos de pirimidina para o tratamento de inflamação
DOP2006000061A (es) 2005-03-10 2006-09-30 Bayer Pharmaceuticals Corp Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AU2006251624A1 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101711241A (zh) 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
US8263585B2 (en) 2007-05-04 2012-09-11 Novartis Ag Organic compounds
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same

Also Published As

Publication number Publication date
US20130338159A1 (en) 2013-12-19
AU2011346567A1 (en) 2013-07-25
WO2012085815A1 (en) 2012-06-28
EA201390917A1 (ru) 2013-12-30
US8901147B2 (en) 2014-12-02
EP2655340B1 (en) 2015-01-21
CA2822565A1 (en) 2012-06-28
BR112013015449A2 (pt) 2016-09-20
CN103270026A (zh) 2013-08-28
EP2655340A1 (en) 2013-10-30
US20140155402A1 (en) 2014-06-05
US8685993B2 (en) 2014-04-01
JP2014500308A (ja) 2014-01-09
KR20130130030A (ko) 2013-11-29

Similar Documents

Publication Publication Date Title
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2011009796A (es) Inhibidores de la cinasa pi3.
PH12014502733A1 (en) Neprilysin inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
PH12015500260A1 (en) Neprilysin inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY165087A (en) Neprilysin inhibitors
MY170935A (en) Neprilysin inhibitors
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
NZ703064A (en) Inhibitors of hepatitis c virus
SG191175A1 (en) Neprilysin inhibitors
IN2014KN00948A (es)
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
MY187718A (en) Pharmaceutical formulations
MX2013012588A (es) Inhibidores de cinasa.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MY160392A (en) Triptolide prodrugs
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2013074905A3 (en) Compounds, compositions, pharmaceutical compositions, and methods of use
MX2013006185A (es) Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal